SCIASCIA THOMAS 4
4 · Trevi Therapeutics, Inc. · Filed Aug 16, 2024
Insider Transaction Report
Form 4
SCIASCIA THOMAS
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-08-16$2.76/sh−18,660$51,440→ 220,315 total - Sale
Common Stock
2024-08-14$2.75/sh−100$275→ 220,315 total - Sale
Common Stock
2024-08-15$2.79/sh−12,745$35,513→ 220,315 total - Exercise/Conversion
Common Stock
2024-08-14$1.43/sh+100$143→ 220,415 total - Exercise/Conversion
Common Stock
2024-08-15$1.43/sh+12,745$18,225→ 233,060 total - Exercise/Conversion
Common Stock
2024-08-16$1.43/sh+18,660$26,684→ 238,975 total - Exercise/Conversion
Stock Option (right to buy)
2024-08-15−12,745→ 35,156 totalExercise: $1.43Exp: 2024-11-24→ Common Stock (12,745 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-08-14−100→ 47,901 totalExercise: $1.43Exp: 2024-11-24→ Common Stock (100 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-08-16−18,660→ 16,496 totalExercise: $1.43Exp: 2024-11-24→ Common Stock (18,660 underlying)
Footnotes (4)
- [F1]Includes 5,882 shares purchased through the Issuer's employee stock purchase plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.8020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.